Grünenthal receives FDA Orphan Drug and Rare Pediatric Disease Designations for Tegacorat for the Treatment of Duchenne Muscular Dystrophy

Aachen, 08 July 2026 – Grünenthal announced today that its investigational compound tegacorat (GRM-01) received Orphan Drug and Rare Pediatric Disease Designations from the US Food and Drug Administration (FDA) for the treatment of Duchenne muscular dystrophy (DMD).

Tegacorat, a non-steroidal Selective Glucocorticoid Receptor Agonist and Modulator (SEGRAM), is an orally available investigational compound being developed to provide an alternative to glucocorticoid-based treatments such as prednisone, the current standard of care in DMD.

Conventional glucocorticoids bind to the glucocorticoid receptor and influence gene expression. Among other mechanisms, this triggers two patterns of activity: transrepression, mainly linked to anti-inflammatory effects, and transactivation, predominantly associated with metabolic and growth-related side effects. In contrast, SEGRAMs are designed to influence receptor activity in a way that emphasises anti-inflammatory pathways. While this has not yet been established in clinical trials, it may allow for more efficacious dosing than current standard treatments and potentially cause fewer side effects. 

“With the current standard of care, people affected by DMD, their caregivers and clinicians must constantly balance efficacy and the burden of side effects as they pursue the essential goal of preserving muscle function,” says Uli Brödl, Chief Scientific Officer at Grünenthal. “We aim to address the unmet need for a long-term therapy option with potent anti-inflammatory efficacy while reducing dose- and duration dependent side effects. The Orphan Drug and Rare Pediatric Disease designations are an important milestone in the development of tegacorat.”

Grünenthal is currently preparing a Phase II trial to investigate the efficacy, safety and tolerability of tegacorat in Duchenne muscular dystrophy. The trial is expected to commence later in 2026 at centres in the US and Europe.